Results 41 to 50 of about 3,573 (200)
Assessment and characteristics of Erenumab therapy on migraine management
Saudi Pharmaceutical Journal, 2022 Background: Migraine is one of the neurological diseases that have a negative impact on subjects’ productivity and daily activity of patients. Introducing monoclonal antibodies as a valuable option for resolving the persistent problem of migraine is ...
Haitham Saeed +3 more
doaj +1 more source
Gender aspects of CGRP in migraine [PDF]
, 2017 Background: Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood.
Labastida-Ramírez, A. (Alejandro) +3 more
core +2 more sources
Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index [PDF]
, 2022 Introduction: Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden
Caponnetto, Valeria +7 more
core +1 more source
Visual hypersensitivity in patients treated with anti-calcitonin gene–related peptide (receptor) monoclonal antibodies [PDF]
, 2023 Objective: To evaluate the effect of treatment with anti-calcitonin gene–related peptide (CGRP; receptor) antibodies on visual hypersensitivity in patients with migraine.
Carpay, Johannes A. +4 more
core +2 more sources
Neurologijos seminarai, 2023 Background. Migraine is a primary headache disorder described by episodic attacks that can progress to chronic migraine. Preventive treatment of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) is currently being widely ...
V. Karpavičiūtė +2 more
doaj +3 more sources
Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine’s Prophylaxis [PDF]
, 2021 open7noBackground: to research retrospectively the efficacy of Erenumab’s treatment, thus allowing to describe a summary more in line with the reality observed every day in clinical practice, relative to a sample of patients widely heterogeneous.
Bufarini, Celestino +6 more
core +1 more source
Improved osteoarthritis during erenumab treatment for migraine: a case report
Case Reports in Neurology, 2023 Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis is yet unknown.
Frederik Thal Jantzen +3 more
doaj +1 more source
Frontiers in Neurology, 2021 Erenumab is the first human monoclonal antibody to be approved as a selective therapy for migraine prophylaxis in adults. This study assessed, in a real-world setting, the efficacy of erenumab and its impact on the quality of life (QoL) of Cypriot ...
Andria Tziakouri +3 more
doaj +1 more source
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience [PDF]
, 2022 Background: Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment resumption.
Mecklenburg, Jasper +7 more
core +1 more source
Cephalalgia Reports, 2021 Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive treatment of migraine.
Stewart J Tepper +6 more
doaj +1 more source